Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

NASDAQ BCLI opened at $1.80 on Friday. The business’s fifty day moving average price is $1.99 and its 200-day moving average price is $2.69. The stock has a market capitalization of $10.26 million, a price-to-earnings ratio of -0.38 and a beta of 0.26. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.89.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.